Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? Have Watchlists? Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s stock price shot up 6.6% during mid-day trading on Monday . Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? AKBA exchanged 5511687 shares on hands in most recent trading session and … Trades from $ 1 Akebia Therapeutics, Inc. (AKBA - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on … Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Analysts have given the company’s stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10. Subscriber Agreement & Terms of Use, By using this site you agree to the November 18, 2020. AKBA 3.39 0.09 (2.73%). Source: Kantar Media. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. View which stocks have been most impacted by COVID-19. AKBA, Akebia Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Do … Since then, AKBA shares have decreased by 60.7% and is now trading at $2.73. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More, Akebia Falls as Vadadustat Fails to Meet Safety Endpoint, Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More, Implied Volatility Surging for Akebia (AKBA) Stock Options, Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates, Encompass Health Continues to Strengthen Presence in Florida. Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 203.41%. ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. For the best MarketWatch.com experience, please update to a modern browser. Fundamental company data and analyst estimates provided by FactSet. Investors in Akebia Therapeutics (NASDAQ:AKBA), Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. View today's stock price, news and analysis for Akebia Therapeutics Inc. (AKBA). Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news and financial information from CNBC. Akebia Therapeutics, Inc. is down ~75% from its 2020 highs after its oral anemia candidate vadadustat failed to achieve safety non-inferiority versus standard of care in CKD-NDD patients. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Akebia Therapeutics, Inc. real time quote is equal to 3.390 USD at 2020-11-29, but your current investment may be devalued in the future. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Create a list of the investments you want to track. International stock quotes are delayed as per exchange requirements. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Akebia Therapeutics, (AKBA) disclosed a change of 5.00% and its listed share value at $2.73 in the recent trade transaction. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. This company belong to USA Country and part of Healthcare sector. If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. Its products include Auryxia and Vadadustat. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Akebia Therapeutics. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Cookie Notice. Akebia Therapeutics presently has a consensus rating of Buy and an average price target of $9.75. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The fund owned 719,317 shares of the biopharmaceutical company’s stock after buying an additional 715,611 shares during the period. The company’s stock price has collected 13.39% of gains in the last five trading sessions. Intraday Data provided by FACTSET and subject to terms of use. 8,047,847 shares traded hands during trading, an increase of 130% from the average session volume of 3,494,822 shares. Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities, Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. CAMBRIDGE - Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... | November 25, 2020 Intraday data delayed at least 15 minutes or per exchange requirements. Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Visit a quote page and your recently viewed tickers will be displayed here. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. All rights reserved. Log in to see them here or sign up to get started. If you are looking for stocks with good return, Akebia Therapeutics, Inc. stock can be a bad, high-risk 1-year investment option. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Privacy Notice, and The share float percentage for the stock currently stands at 81.57%. 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Dow sinks 272 points, but books best November since 1928, and best month since ’87, Arizona, Wisconsin certify election win for Biden, New York zeroes in on hospitals as COVID-19 cases climb, K12 paying ransom to cybercriminals following breach, Tesla stock to be added all at once to S&P 500, Powell says Fed actions unlocked $2 trillion to support economy, Zoom Stocks Falls Despite Another Earnings Blowout, Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho, Akebia Therapeutics started at overweight with $12 stock price target at J.P. Morgan, Akebia Therapeutics started at outperform with $18 stock price target at Raymond James, Akebia and Keryx expect deal to close by year-end, Akebia and Keryx say deal will create company with pro forma equity value of about $1.3 bln, Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal, Akebia Therapeutics' stock soars 78% to lead Nasdaq gainers after positive trial results, Akebia's shares jump on late-stage clinical trial results for kidney disease drug, Akebia shares jump on expanded anemia drug deal with Otsuka, Akebia Shares Could More Than Double in a Year. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. A number of […] The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. The company traded as high as $3.18 and last traded at $3.07. The high price target for AKBA is $18.00 and the low price target for AKBA is … All quotes are in local exchange time. Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. There are currently no items in this Watchlist. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. AKBA is not currently paying a regular dividend. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Get Akebia Therapeutics alerts: Shares of NASDAQ AKBA opened at $2.38 on Thursday. The stock had previously closed at $2.88. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -1.03% from its latest closing price compared to the recent 1-year high of $13.71. Despite being -2.12% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 19 when the AKBA stock price touched $3.96-6 or saw a rise of 6.57%. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. Several other experts on Wall Street have posted such reports regarding the AKBA shares. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. Something went wrong while loading Watchlist. Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are … Acadian Asset Management LLC lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 19,309.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know. Do Options Traders Know Something About Akebia (AKBA) Stock We Don't? This browser is no longer supported at MarketWatch. Press Release reported on 11/18/20 that Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500(TM) Let’s start up with the current stock price of Akebia Therapeutics Inc. (AKBA), which is $3.15 to be very precise. Source: FactSet. Historical and current end-of-day data provided by FACTSET. Post-Market 0.02 (0.59%) A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Copyright 2019© FactSet Research Systems Inc. All rights reserved. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry, Akebia Shares Climb on Positive Anemia Drug Study Results, Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. The Stock rose vividly during the last session to $3.19 after opening rate of $3.16 while the lowest price it went was recorded $3.01 before closing at $3.08. Get Our PREMIUM Forecast Now, from ONLY $6.69! Data may be intentionally delayed pursuant to supplier requirements. Copyright © 2020 MarketWatch, Inc. All rights reserved. Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Barron's also provides information on historical stock ratings, … Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders.